


## CLAIMS

1. Neuroactive substance characterised in that it complies with the formula (0)




5

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are identical or different and are methyl or ethyl radicals.


2. Neuroactive substance according to claim 1 characterised in that it complies with the formula

10 (I)



3. Neuroactive substance according to claim 2  
15 characterised in that it consists of 6S-acetyl-4R,5R-dimethyl-1R(10S)-epoxy-2R-hydroxy-7R-

acetoxydecahydronaphthalene according to formula  
(II)



5

4. Substance according to claim 3 characterised in that it is extracted from the Cnidarian *Rhytisma fulvum*.

10 5. Substance according to claim 1, 2 or 3 characterised in that it is produced by chemical synthesis.

6. Use of a substance according to any of claims 1, 2 or 3 to produce a pharmacological reagent.

15 7. Use according to claim 6 characterised in that said pharmacological reagent is a selective transient low voltage activated calcium membrane channel activator.

20 8. Use of a substance according to any of claims 1, 2 or 3 to produce an insecticide.

9. Use according to claim 8 characterised in that said substance is used in association with another insecticide.

10. Use of a substance according to claim 1, 2 or 3 to produce a medicinal product intended to treat diseases associated with neuronal excitability disorders.

5 11. Use according to claim 10 to produce a dopaminergic neuron activator medicinal product.

12. Use according to claim 11 to produce a medicinal product intended to treat Parkinson's disease.

10 13. Use according to claim 10 to produce a medicinal product intended to treat the decrease in the action potential frequency of pacemaker activity neurons.